Soluble Guanylate Cyclase Stimulators in Heart Failure

被引：12

作者：

Kansakar, Sajog ^{[1
]}

Guragain, Ashish ^{[1
]}

Verma, Deepak ^{[2
]}

Sharma, Prabhat ^{[1
,3
]}

Dhungana, Bibek ^{[4
]}

Bhattarai, Bidit ^{[5
]}

Yadav, Sunil ^{[6
]}

Gautam, Ishant ^{[7
]}

机构：

[1] Manipal Coll Med Sci, Internal Med, Pokhara, Nepal

[2] Calif Inst Behav Neurosci & Psychol, Internal Med Family Med, Fairfield, CA USA

[3] Shankarapur Hosp, Internal Med, Kathmandu, Nepal

[4] KIST Med Coll, Internal Med, Lalitpur, Nepal

[5] Venus Hosp, Internal Med, Kathmandu, Nepal

[6] Topa Primary Hlth Ctr, Internal Med, Rajbiraj, Nepal

[7] Bhaktapur Hosp, Internal Med, Bhaktapur, Nepal

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 09期

关键词：

heart failure with reduced ejection fraction (hfref); heart failure with preserved ejection fraction (hfpef); heart failure; guanylate cyclase stimulators; vericiguat; PRESERVED EJECTION FRACTION; NITRIC-OXIDE; VERICIGUAT; PATHOPHYSIOLOGY; CAPACITY; PLACEBO;

D O I：

10.7759/cureus.17781

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure has a high global burden of morbidity and mortality. Despite significant advances in medical management of heart failure, the prognosis remains poor. This justifies the search for newer therapeutic agents. Recently, soluble guanylate stimulators have demonstrated favorable results in clinical trials. This article aims to summarize the guanylate cyclase signaling pathway, the role of soluble guanylate cyclase stimulators in heart failure, and data from recent clinical trials of these drugs. We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. There appears to be no benefit of these drugs in patients with heart failure with preserved ejection fraction.

引用

页数：7

共 50 条

[21] Soluble guanylate cyclase stimulators and their potential use: a patent review
Sandner, Peter
Vakalopoulos, Alexandros
Hahn, Michael G.
Stasch, Johannes-Peter
Follmann, Markus
EXPERT OPINION ON THERAPEUTIC PATENTS, 2021, 31 (03) : 203 - 222
[22] The discovery and characterization of novel soluble guanylate cyclase stimulators
Jaime L Masferrer
BMC Pharmacology and Toxicology, 16 (Suppl 1)
[23] Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction
Tran, Bao-Anh
Serag-Bolos, Erini S.
Fernandez, Joel
Miranda, Aimon C.
JOURNAL OF PHARMACY PRACTICE, 2023, 36 (04) : 905 - 914
[24] Is there a role for soluble guanylate cyclase stimulators in acute pulmonary embolism?
Appavu, Samuel K.
CRITICAL CARE MEDICINE, 2011, 39 (12) : 2773 - 2774
[25] Activation mechanism of human soluble guanylate cyclase by stimulators and activators
Liu, Rui
Kang, Yunlu
Chen, Lei
NATURE COMMUNICATIONS, 2021, 12 (01)
[26] Praliciguat and Soluble Guanylate Cyclase Stimulators for Peripheral Artery Disease
Kosmac, Kate
Ismaeel, Ahmed
Kim-Shapiro, Daniel B.
McDermott, Mary M.
CIRCULATION RESEARCH, 2023, 132 (01) : 49 - 51
[27] Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs
Tawa, Masashi
Nakagawa, Keisuke
Ohkita, Mamoru
HYPERTENSION RESEARCH, 2025, : 1458 - 1470
[28] From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Sandner, Peter
BIOLOGICAL CHEMISTRY, 2018, 399 (07) : 679 - 690
[29] Soluble Guanylate Cyclase Activation With Cinaciguat A New Approach to the Treatment of Decompensated Heart Failure
Hingorany, Shipra
Frishman, William H.
CARDIOLOGY IN REVIEW, 2011, 19 (01) : 23 - 29
[30] The efficacy and safety of soluble guanylate cyclase modulation in patients with heart failure: a comprehensive meta-analysis of randomized controlled trials
Arayici, Mehmet Emin
Gunes, Hakan
Ellidokuz, Hulya
Yilmaz, Mehmet Birhan
SCIENTIFIC REPORTS, 2024, 14 (01)

← 1 2 3 4 5 →